Google
GILD 株価分析 — Gilead Sciences Inc (Healthcare >> Drug Manufacturers - General)
GILD に関するよくある質問
GILDのPER（株価収益率）は？
Gilead Sciences Inc（GILD）は現在PER 17.69倍で取引されています。
GILDのROE（自己資本利益率）は？
Gilead Sciences IncのROEは39.19%です。
GILDの配当利回りは？
Gilead Sciences Incの配当利回りは2.40%です。
GILDの品質スコア（Quality Score）は？
当社のAIはGILDの総合財務品質を100点中92点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
GILDは今が買い時ですか？
当社AIのタイミングスコアは100点中50点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
GILDはどのセクターに属しますか？
Gilead Sciences IncはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NASDAQ市場）
GILD AI Analysis Summary
Our AI summary for GILD: Gilead Sciences Inc (NASDAQ), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 17.69, ROE of 39.19%, a dividend yield of 2.40%. Its financial Quality Score stands at 92/100 — fundamentals stronger than most of the market. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 130.21
Price
-1.07
(-0.82%)
Day Change
|
|
|---|
GILD, ファンダメンタルスコアはexcellent ( ファンダメンタル = 92) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROAがROEに比べて低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not quite good , and ability to make profit is very good , ...
| Deepscope 分析 |
|
63% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
570
|
| Magic Formula Rank by ROE |
570
|
| Magic Formula Rank by ROIC |
702
|
| Price | 130.21 |
| PBV / Sector |
6.96 / 2.68
|
| Earning Per Share | 7.36 |
| PE / Sector |
17.69 / 27.65
|
| PEG or PE/Growth / Sector |
0.03 / 0.28
GREAT
|
| Average 1M Daily Value |
837.66 M
|
| Average 1W Daily Value |
805.49 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
56% |
| ポイントになる統計 |
|
81% |
| 配当 |
|
12% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:54 |
| Symbol | GILD |
| Name | GILEAD SCIENCES INC |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NASDAQ |
| Listed Shares | 1,241.57 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 162,993.29 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 333 Lakeside Drive, Foster City, CA, United States, 94404
Phone: 650 574 3000
Website: https://www.gilead.com
Employees: 17,000
Description: Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
